Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma

Hepatocellular carcinoma is the seventh most common type of cancer in the world, with limited treatment options. A promising strategy to treat cancer is to associate chemotherapeutics and plant bioactive compounds. Here, we examined whether diallyl disulfide (DADS; 50–200 μM) and sorafenib (SORA; 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado, Ana Rita Thomazela, Tuttis, Katiuska, Santos, Patrick Wellington da Silva, Aissa, Alexandre Ferro, Antunes, Lusânia Maria Greggi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788602/
https://www.ncbi.nlm.nih.gov/pubmed/36559076
http://dx.doi.org/10.3390/pharmaceutics14122582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788602/
https://www.ncbi.nlm.nih.gov/pubmed/36559076
http://dx.doi.org/10.3390/pharmaceutics14122582

Ejemplares similares